161 related articles for article (PubMed ID: 20652353)
1. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine.
Gentile G; Borro M; Lala N; Missori S; Simmaco M; Martelletti P
J Headache Pain; 2010 Oct; 11(5):431-5. PubMed ID: 20652353
[TBL] [Abstract][Full Text] [Related]
2. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.
Gentile G; Missori S; Borro M; Sebastianelli A; Simmaco M; Martelletti P
J Headache Pain; 2010 Apr; 11(2):151-6. PubMed ID: 20213484
[TBL] [Abstract][Full Text] [Related]
3. The serotonin transporter gene polymorphism STin2 VNTR confers an increased risk of inconsistent response to triptans in migraine patients.
Terrazzino S; Viana M; Floriddia E; Monaco F; Mittino D; Sances G; Tassorelli C; Nappi G; Rinaldi M; Canonico PL; Genazzani AA
Eur J Pharmacol; 2010 Sep; 641(2-3):82-7. PubMed ID: 20488209
[TBL] [Abstract][Full Text] [Related]
4. Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy.
Gentile G; Borro M; Simmaco M; Missori S; Lala N; Martelletti P
Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):39-47. PubMed ID: 21142809
[TBL] [Abstract][Full Text] [Related]
5. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
6. Negative predictors of clinical response to triptans in patients with migraine.
Ishii M; Sakairi Y; Hara H; Imagawa A; Shimizu S; Takahashi J; Nagamine A; Naito Y; Masuda Y; Usami S; Kiuchi Y
Neurol Sci; 2012 Apr; 33(2):453-61. PubMed ID: 21822697
[TBL] [Abstract][Full Text] [Related]
7. Gene variants with suicidal risk in a sample of subjects with chronic migraine and affective temperamental dysregulation.
Serafini G; Pompili M; Innamorati M; Gentile G; Borro M; Lamis DA; Lala N; Negro A; Simmaco M; Girardi P; Martelletti P
Eur Rev Med Pharmacol Sci; 2012 Oct; 16(10):1389-98. PubMed ID: 23104655
[TBL] [Abstract][Full Text] [Related]
8. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
[TBL] [Abstract][Full Text] [Related]
10. G protein beta3 polymorphism and triptan response in cluster headache.
Schürks M; Kurth T; Stude P; Rimmbach C; de Jesus J; Jonjic M; Diener HC; Rosskopf D
Clin Pharmacol Ther; 2007 Oct; 82(4):396-401. PubMed ID: 17361120
[TBL] [Abstract][Full Text] [Related]
11. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
[TBL] [Abstract][Full Text] [Related]
12. Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache.
Cargnin S; Pautasso C; Viana M; Sances G; Mittino D; Cantello R; Tassorelli C; Nappi G; Terrazzino S
Headache; 2015 May; 55(5):658-68. PubMed ID: 25881990
[TBL] [Abstract][Full Text] [Related]
13. No evidence of an association between a functional monoamine oxidase a gene polymorphism and completed suicides.
Ono H; Shirakawa O; Nishiguchi N; Nishimura A; Nushida H; Ueno Y; Maeda K
Am J Med Genet; 2002 Apr; 114(3):340-2. PubMed ID: 11920860
[TBL] [Abstract][Full Text] [Related]
14. Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine-Associated Nausea and Prior Triptan Use on Efficacy.
Lipton RB; Schmidt P; Diener HC
Headache; 2017 May; 57(5):756-765. PubMed ID: 28386945
[TBL] [Abstract][Full Text] [Related]
15. Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine.
Mei D; Ferraro D; Zelano G; Capuano A; Vollono C; Gabriele C; Di Trapani G
Clin Neuropharmacol; 2006; 29(5):269-75. PubMed ID: 16960472
[TBL] [Abstract][Full Text] [Related]
16. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
Lee JH; Shewale AR; Barthold D; Devine B
Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
[TBL] [Abstract][Full Text] [Related]
17. Haplotypes of the monoamine oxidase genes and the risk for substance use disorders.
Vanyukov MM; Maher BS; Devlin B; Tarter RE; Kirillova GP; Yu LM; Ferrell RE
Am J Med Genet B Neuropsychiatr Genet; 2004 Feb; 125B(1):120-5. PubMed ID: 14755456
[TBL] [Abstract][Full Text] [Related]
18. Triptans for Acute Migraine Headache: Current Experience With Triptan Use and Prescription Habits in a Tertiary Care Headache Outpatient Clinic: An Observational Study.
Fischer M; Frank F; Wille G; Klien S; Lackner P; Broessner G
Headache; 2016 Jun; 56(6):952-60. PubMed ID: 27091593
[TBL] [Abstract][Full Text] [Related]
19. Multi-omic analyses of triptan-treated migraine attacks gives insight into molecular mechanisms.
Kogelman LJA; Falkenberg K; Ottosson F; Ernst M; Russo F; Stentoft-Hansen V; Demharter S; Tfelt-Hansen P; Cohen AS; Olesen J; Hansen TF
Sci Rep; 2023 Jul; 13(1):12395. PubMed ID: 37524744
[TBL] [Abstract][Full Text] [Related]
20. Triptan non-response in specialized headache care: cross-sectional data from the DMKG Headache Registry.
Ruscheweyh R; Gossrau G; Dresler T; Freilinger T; Förderreuther S; Gaul C; Kraya T; Neeb L; Ruschil V; Straube A; Scheidt J; Jürgens TP
J Headache Pain; 2023 Oct; 24(1):135. PubMed ID: 37817093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
